These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21859992)

  • 1. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14.
    Lipton A; Chapman JA; Demers L; Shepherd LE; Han L; Wilson CF; Pritchard KI; Leitzel KE; Ali SM; Pollak M
    J Clin Oncol; 2011 Sep; 29(27):3605-10. PubMed ID: 21859992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
    Garnero P; Mulleman D; Munoz F; Sornay-Rendu E; Delmas PD
    J Bone Miner Res; 2003 Oct; 18(10):1789-94. PubMed ID: 14584889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
    Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
    Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
    Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
    Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
    Amin S; Riggs BL; Melton LJ; Achenbach SJ; Atkinson EJ; Khosla S
    J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-telopeptides of type I collagen in postmenopausal women: an experience in a Tunisian clinical laboratory.
    Bouzid K; Bahlous A; Kalaï E; Fellah H; Sahli H; Sellami S; Abdelmoula J
    Tunis Med; 2010 Jul; 88(7):467-9. PubMed ID: 20582880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
    Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
    Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A lifecourse study of bone resorption in men ages 49-51years: the Newcastle Thousand Families cohort study.
    Pearce MS; Relton CL; Groom A; Peaston RT; Francis RM
    Bone; 2010 Apr; 46(4):952-6. PubMed ID: 20080222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.